2024 Q3 Form 10-Q Financial Statement
#000117992924000123 Filed on July 25, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| Revenue | $10.34B | $9.880B |
| YoY Change | 20.96% | 18.65% |
| Cost Of Revenue | $8.643B | $8.368B |
| YoY Change | 18.3% | 18.9% |
| Gross Profit | $1.697B | $1.512B |
| YoY Change | 36.63% | 17.3% |
| Gross Profit Margin | 16.41% | 15.3% |
| Selling, General & Admin | $1.184B | $987.0M |
| YoY Change | 51.02% | 25.41% |
| % of Gross Profit | 69.77% | 65.28% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $47.00M | $46.00M |
| YoY Change | 11.9% | 9.52% |
| % of Gross Profit | 2.77% | 3.04% |
| Operating Expenses | $1.230B | $1.076B |
| YoY Change | 48.91% | 29.79% |
| Operating Profit | $467.0M | $434.0M |
| YoY Change | 30.08% | -5.65% |
| Interest Expense | -$29.00M | -$28.00M |
| YoY Change | -207.41% | 3.7% |
| % of Operating Profit | -6.21% | -6.45% |
| Other Income/Expense, Net | -$28.00M | |
| YoY Change | 3.7% | |
| Pretax Income | $438.0M | $406.0M |
| YoY Change | 31.93% | -2.4% |
| Income Tax | $112.0M | $105.0M |
| % Of Pretax Income | 25.57% | 25.86% |
| Net Earnings | $326.0M | $301.0M |
| YoY Change | 33.06% | -2.59% |
| Net Earnings / Revenue | 3.15% | 3.05% |
| Basic Earnings Per Share | $5.67 | $5.18 |
| Diluted Earnings Per Share | $5.65 | $5.17 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 58.60M shares | 58.60M shares |
| Diluted Shares Outstanding | 57.70M shares | 58.20M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $9.214B | $8.701B |
| YoY Change | -4.77% | -1.08% |
| Cash & Equivalents | $4.732B | $4.354B |
| Short-Term Investments | $4.482B | $4.347B |
| Other Short-Term Assets | $408.0M | $399.0M |
| YoY Change | 22.89% | 53.46% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $3.259B | $3.231B |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $12.88B | $12.33B |
| YoY Change | 3.31% | 7.78% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $306.0M | $305.0M |
| YoY Change | 5.52% | 7.02% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $132.0M | $136.0M |
| YoY Change | 5.6% | -76.83% |
| Total Long-Term Assets | $2.877B | $2.854B |
| YoY Change | 19.78% | 28.56% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $12.88B | $12.33B |
| Total Long-Term Assets | $2.877B | $2.854B |
| Total Assets | $15.76B | $15.19B |
| YoY Change | 5.97% | 11.16% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.215B | $973.0M |
| YoY Change | 11.47% | 13.54% |
| Accrued Expenses | ||
| YoY Change | ||
| Deferred Revenue | $364.0M | $13.00M |
| YoY Change | -47.32% | -96.86% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $8.337B | $7.836B |
| YoY Change | -1.83% | 3.97% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $2.332B | $2.181B |
| YoY Change | 7.02% | -8.4% |
| Other Long-Term Liabilities | $122.0M | $122.0M |
| YoY Change | 0.83% | 0.0% |
| Total Long-Term Liabilities | $2.454B | $2.303B |
| YoY Change | 6.7% | -7.99% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $8.337B | $7.836B |
| Total Long-Term Liabilities | $2.454B | $2.303B |
| Total Liabilities | $10.99B | $10.34B |
| YoY Change | -0.03% | 3.01% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $4.326B | $4.489B |
| YoY Change | 17.84% | 31.03% |
| Common Stock | $453.0M | $439.0M |
| YoY Change | 21.45% | 28.74% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $4.770B | $4.843B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $15.76B | $15.19B |
| YoY Change | 5.97% | 11.16% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $326.0M | $301.0M |
| YoY Change | 33.06% | -2.59% |
| Depreciation, Depletion And Amortization | $47.00M | $46.00M |
| YoY Change | 11.9% | 9.52% |
| Cash From Operating Activities | $873.0M | -$219.0M |
| YoY Change | -8.01% | -144.97% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $35.00M | $27.00M |
| YoY Change | 34.62% | -12.9% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$13.00M | $80.00M |
| YoY Change | -94.88% | -175.47% |
| Cash From Investing Activities | -$48.00M | $53.00M |
| YoY Change | -82.86% | -138.69% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -364.0M | 12.00M |
| YoY Change | 5966.67% | 20.0% |
| NET CHANGE | ||
| Cash From Operating Activities | 873.0M | -219.0M |
| Cash From Investing Activities | -48.00M | 53.00M |
| Cash From Financing Activities | -364.0M | 12.00M |
| Net Change In Cash | 461.0M | -154.0M |
| YoY Change | -30.47% | -142.78% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $873.0M | -$219.0M |
| Capital Expenditures | $35.00M | $27.00M |
| Free Cash Flow | $838.0M | -$246.0M |
| YoY Change | -9.21% | -153.95% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q2 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
43000000 | usd |
| CY2023Q2 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
17000000 | usd |
| us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
81000000 | usd | |
| CY2024Q2 | moh |
Pharmacy Claims Payable
PharmacyClaimsPayable
|
232000000 | usd |
| CY2024Q2 | moh |
Capitation Claims Payable
CapitationClaimsPayable
|
158000000 | usd |
| CY2024Q2 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
4577000000 | usd |
| us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
0 | usd | |
| us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
0 | usd | |
| us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
33000000 | usd | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2964000000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
321000000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
309000000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-21000000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
45000000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3621000000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
602000000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
630000000 | usd | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
91000000 | usd | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
86000000 | usd | |
| us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
-21000000 | usd | |
| us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
4000000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
68000000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
55000000 | usd | |
| us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
4000000 | usd | |
| us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
5000000 | usd | |
| us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
5000000 | usd | |
| us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
83000000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-16000000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-6000000 | usd | |
| us-gaap |
Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
|
-48000000 | usd | |
| us-gaap |
Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
|
149000000 | usd | |
| moh |
Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
|
-43000000 | usd | |
| moh |
Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
|
510000000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-307000000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-208000000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-405000000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
55000000 | usd | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
1000000 | usd | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
202000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
1403000000 | usd | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
594000000 | usd | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
924000000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
506000000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
546000000 | usd | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
295000000 | usd | |
| us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
54000000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
63000000 | usd | |
| us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
-2000000 | usd | |
| us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
-2000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-435000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-439000000 | usd | |
| moh |
Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
|
56000000 | usd | |
| moh |
Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
|
59000000 | usd | |
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
6000000 | usd | |
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
4000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-50000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-55000000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-490000000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
909000000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4908000000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4048000000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4418000000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4957000000 | usd |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
4 | segment | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. | ||
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4354000000 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4910000000 | usd |
| CY2024Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
64000000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
47000000 | usd |
| CY2024Q2 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
3231000000 | usd |
| CY2023Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
3104000000 | usd |
| CY2024Q2 | moh |
Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
|
1261000000 | usd |
| CY2023Q4 | moh |
Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
|
1344000000 | usd |
| CY2024Q2 | moh |
Percent Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
PercentDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
|
0.85 | |
| CY2023Q4 | moh |
Percent Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
PercentDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
|
0.85 | |
| CY2024Q2 | moh |
Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
|
51000000 | usd |
| CY2023Q4 | moh |
Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
|
64000000 | usd |
| CY2024Q2 | moh |
Percent Due To Government Agencies Medicare Medical Loss Ratio Of Marketplace
PercentDueToGovernmentAgenciesMedicareMedicalLossRatioOfMarketplace
|
0.80 | |
| CY2023Q4 | moh |
Percent Due To Government Agencies Medicare Medical Loss Ratio Of Marketplace
PercentDueToGovernmentAgenciesMedicareMedicalLossRatioOfMarketplace
|
0.80 | |
| CY2024Q2 | moh |
Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
|
91000000 | usd |
| CY2023Q4 | moh |
Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
|
66000000 | usd |
| CY2024Q2 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
|
-348000000 | usd |
| CY2024Q2 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
|
363000000 | usd |
| CY2024Q2 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Net Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetReceivable
|
15000000 | usd |
| CY2023Q4 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
|
-201000000 | usd |
| CY2023Q4 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
|
241000000 | usd |
| CY2023Q4 | moh |
Affordable Care Act Premium Stabilization Program Risk Adjustment Net Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetReceivable
|
40000000 | usd |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div> | ||
| moh |
Investments Maturity Period
InvestmentsMaturityPeriod
|
P15Y | ||
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
301000000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
309000000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
602000000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
630000000 | usd | |
| CY2024Q1 | moh |
Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
|
58100000 | shares |
| CY2023Q1 | moh |
Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
|
57700000 | shares |
| CY2023Q4 | moh |
Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
|
57800000 | shares |
| CY2022Q4 | moh |
Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
|
57400000 | shares |
| CY2024Q2 | moh |
Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
|
0 | shares |
| CY2023Q2 | moh |
Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
|
0 | shares |
| moh |
Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
|
200000 | shares | |
| moh |
Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
|
200000 | shares | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58100000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
57700000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58000000.0 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
57600000 | shares | |
| CY2024Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
100000 | shares |
| CY2023Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
200000 | shares |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
300000 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
400000 | shares | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58200000 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
57900000 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58300000 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58000000.0 | shares | |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
5.18 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
5.37 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
10.38 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
10.95 | ||
| CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
5.17 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
5.35 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
10.33 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
10.87 | ||
| CY2024Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
208000 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
140000 | shares | |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
|
4459000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
9000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
121000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
4347000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
|
4367000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
21000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
129000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
4259000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
666000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
657000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
2273000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
2225000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
|
452000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
|
446000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
|
1068000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
|
1019000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
|
4459000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
|
4347000000 | usd |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
471000000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
292000000 | usd | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
35000000 | usd | |
| us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
254000000 | usd | |
| us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
3000000 | usd | |
| us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
10000000 | usd | |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
792000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
7000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
538 | position |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
2395000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
114000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
|
1272 | position |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
386000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
3000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
258 | position |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
2431000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
126000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
|
1261 | position |
| CY2024Q2 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
268000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
|
184000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
|
78000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
|
6000000 | usd |
| us-gaap |
Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> | ||
| CY2024Q2 | moh |
Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
|
3233000000 | usd |
| CY2023Q4 | moh |
Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
|
2901000000 | usd |
| CY2023Q4 | moh |
Pharmacy Claims Payable
PharmacyClaimsPayable
|
202000000 | usd |
| CY2023Q4 | moh |
Capitation Claims Payable
CapitationClaimsPayable
|
100000000 | usd |
| CY2024Q2 | moh |
Other Claims Payable
OtherClaimsPayable
|
954000000 | usd |
| CY2023Q4 | moh |
Other Claims Payable
OtherClaimsPayable
|
1001000000 | usd |
| CY2023Q4 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
4204000000 | usd |
| CY2024Q2 | moh |
Non Risk Provider Payable
NonRiskProviderPayable
|
284000000 | usd |
| CY2023Q4 | moh |
Non Risk Provider Payable
NonRiskProviderPayable
|
481000000 | usd |
| CY2023Q4 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
4204000000 | usd |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
|
17301000000 | usd | |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
|
-519000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
|
16782000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
|
13429000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
|
3161000000 | usd | |
| us-gaap |
Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
|
16590000000 | usd | |
| moh |
Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
|
421000000 | usd | |
| moh |
Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
|
-240000000 | usd | |
| CY2024Q2 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
4577000000 | usd |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
|
14180000000 | usd | |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
|
-271000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
|
13909000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
|
11166000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
|
2650000000 | usd | |
| us-gaap |
Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
|
13816000000 | usd | |
| moh |
Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
|
0 | usd | |
| moh |
Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
|
56000000 | usd | |
| CY2023Q2 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
3677000000 | usd |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
|
-519000000 | usd | |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
|
-271000000 | usd | |
| CY2024Q2 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
19000000 | usd |
| CY2023Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
20000000 | usd |
| CY2024Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2181000000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2180000000 | usd |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
4 | segment | |
| CY2024Q2 | us-gaap |
Revenues
Revenues
|
9880000000 | usd |
| CY2023Q2 | us-gaap |
Revenues
Revenues
|
8327000000 | usd |
| us-gaap |
Revenues
Revenues
|
19811000000 | usd | |
| us-gaap |
Revenues
Revenues
|
16476000000 | usd | |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
434000000 | usd |
| CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
443000000 | usd |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
860000000 | usd | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
898000000 | usd | |
| CY2024Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-28000000 | usd |
| CY2023Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-27000000 | usd |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-55000000 | usd | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-55000000 | usd | |
| CY2024Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
406000000 | usd |
| CY2023Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
416000000 | usd |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
805000000 | usd | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
843000000 | usd | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
